PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug

NES-ZIONA, Israel, July 27, /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (OTC Bulletin Board: PBTH) formerly Modigene Inc., today announced that it has entered into an evaluation and option agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the ...

Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters

SAN DIEGO, July 24 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today announced that its underwriters fully exercised their overallotment option to purchase an additional 1,500,000 shares of its common stock in connection with its previously announced public of...

Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies

EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology products, today announced that they have entered into an ev...

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

Cytokinetics Receives Exercise Fee of $50 Million Cytokinetics to Host a Conference Call Tuesday, May 26, 2009 at 9 AM ET SOUTH SAN FRANCISCO, Calif. and THOUSAND OAKS, Calif., May 26 /PRNewswire-FirstCall/ -- Cytokinetics Incorporated (Nasdaq: CYTK ) and Amgen Inc. (Nasdaq: AMGN ) ...

Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers

Z Therapy Whiplash Treatment Center now offers a ground-breaking treatment option for victims of whiplash associated disorders (WAD). With the introduction of a multi-cervical unit (MCU) by BTE Technologies, Z Therapy is the first and only rehabilitation specialist in North Texas to offer this t...

Transgenomic Completes Licensing Option With Dana-Farber Cancer Institute on Cold-PCR for Enrichment of DNA Mutations

OMAHA, Neb., April 7 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO), a leading global biotechnology company, announces that it has completed a licensing option with the Dana-Farber Cancer Institute, Boston, MA with regard to a method known as Cold-PCR. This variation of t...

Empirical Search Strategies Seeks Downside Protection Option at Avigen, Inc.

CHICAGO, March 20 /PRNewswire/ -- Empirical Search Strategies, LP. ("ESS"), the beneficial owner of approximately 2.3% of the Avigen, Inc.'s (Nasdaq: AVGN ) outstanding common stock, has proclaimed their support for a "downside protection" measure described by the Biotechnology Value Fund ("BV...

Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company

WALTHAM, Mass., March 5 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has successfully completed a $38 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P. This announcement follows the initiation of a Phase 1/2 human clin...

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million

CTI to focus on Pixantrone and OPAXIO Approval and Commercialization SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmac...

Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor

FRAZER, Pa., Feb. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc . (Nasdaq: CEPH ) today announced that the company will exercise its option to license worldwide rights to Lupuzor(TM), an investigational medication for the treatment of Systemic Lupus Erythematosus, based on the promising interim...

SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin

CALGARY, Jan. 6 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing protein pharmaceuticals in crop plants, today announced it has received US$2,500,000 from MannKind Corporation (Nasdaq: MNKD ) as consideration for the option agreement and issuance of 2...

Webcast Alert: Isis Pharmaceuticals Announces That Abbott Exercised Its Option to Acquire Ibis Biosciences

CARLSBAD, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announces the following webcast: What: Abbott's exercise of its option to purchase Ibis Biosciences, a subsidiary of Isis. Total acquisition price will be $2...

Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis

Total acquisition price will be $215 million Acquisition will expand Abbott's position in molecular diagnostics for infectious disease CARLSBAD, Calif. and ABBOTT PARK, Ill., Dec. 17 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) and Abbott (NYSE: ABT ) ...

Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics

OMAHA, Neb. and HOUSTON, Dec. 2 /PRNewswire-FirstCall/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO) and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced that Transgenomic has signed a letter of intent to acquire exclusive rights for Power3 Medical's Neurodegenerative Bi...

STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine

WHEAT RIDGE, Colo., Oct. 27 /PRNewswire-FirstCall/ -- GeneThera, Inc. (Pink Sheets: GTHR), announced today that it has signed an agreement with STC.UNM (STC), the technology-transfer arm of the University of New Mexico (UNM), giving GeneThera an option to a license to worldwide development and...

GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimer's Disease Candidate Vaccines

VIENNA, Austria, October 23 /PRNewswire/ -- GlaxoSmithKline Biologicals S.A. (GSK) and AFFiRiS GmbH announced today the execution of a collaboration agreement granting GSK exclusive rights to AFFiRiS's Alzheimer's disease vaccine programmes, aimed at treating Alzheimer's by targeting beta-amyl...

Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles

FAME Data Demonstrates 30% Reduction in Composite Events When Using Routine FFR Guidance in Multi-Vessel Disease WASHINGTON, Oct. 15 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC ) today announced the launch of the PrimeWire(TM) Pressure Guidewire, and the s5-FFR ...

Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo

CAMBRIDGE, Mass., Sept. 15 /PRNewswire/ -- Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that it has met its second milestone in its option agreement with the Novartis Option Fund and will ...

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350

PALO ALTO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 34 non-executive officers due to additional hiring, primarily in connection with...

Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants

Dow AgroSciences Will Sublicense Sangamo's Technology in Plant Agriculture Under the Trademark EXZACT(TM) Precision Traits SAN DIEGO, June 18 /PRNewswire-FirstCall/ -- Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW ), announced today at the 20...

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350

PALO ALTO, Calif., May 28 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 31 non-executive officers due to additional hiring, primarily in connection with ...

Amnis Announces Release of Its Extended Depth of Field Option for The ImageStream(R) System

SEATTLE, May 22 /PRNewswire/ -- Amnis Corporation announced today the commercial release of its Extended Depth of Field (EDF(TM)) option for the ImageStream system. This technology breaks through classical depth of field limitations of high resolution optical systems, thereby improving the per...

American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients

The New Best Practice Statements Were Presented at the AUA Annual Meeting Being Held in Orlando, Florida YOKNEAM, Israel and PLYMOUTH MEETING, Pennsylvania, May 21 /PRNewswire/ -- Galil Medical, a global leader in cryotherapy, announced today that the American Urological Association has intr...

BioMed Realty Trust Announces Exercise of Over-Allotment Option for Common Stock

SAN DIEGO, April 22 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR ) today announced that its underwriters have exercised their over-allotment option to purchase additional shares of common stock in connection with BioMed's previously announced follow-on offering that priced o...

Resverlogix Share Option Extension

TSX Exchange Symbol: RVX CALGARY, April 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that 948,700 stock options due to expire April 25, 2008 will automatically be extended pursuant to the Company's stock option...

Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment

LONDON, April 1, 2008 /PRNewswire/ -- Plethora Solutions Holdings PLC ("Plethora", AIM: PLE), the developer of specialist products for the treatment and management of urological disorders, today announced that it has entered into a revenue interest financing agreement with Paul Capital Healthc...

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350

PALO ALTO, Calif., Feb. 14 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 19 non-executive officer employees due to additional hiring, primarily in connec...

Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity

- Conference call webcast Thursday, January 31, 2008, 8:30 a.m. EST at http://www.isispharm.com CARLSBAD, Calif., Jan. 31 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) announced today that Abbott is investing up to $40 million in Ibis Biosci...

SemBioSys signs option agreement for safflower-produced food ingredient

TSX symbol: SBS CALGARY, Jan. 29 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has signed an option agreement wit...

CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350

PALO ALTO, Calif., Oct. 26 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX ) announced today that, in accordance with Nasdaq marketplace rule 4350, the Company issued new inducement stock options to 14 non-executive officers due to additional hiring, primarily in connection with...

Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis

-MPM Bio IV NVS Strategic Fund L.P. invests $10 million in Radius- CAMBRIDGE, Mass., Sept. 17 /PRNewswire/ -- Radius Health ("Radius") announced today that it has granted Novartis (NYSE: NVS ) an option to obtain an exclusive worldwide license (except Japan) to develop and commercialize al...

Cancer Fighting Nutrition Supplement, Caplex, Offers Cancer Patients A New All-Natural Treatment Option

Millennium Bioceutics, announces the release of it's advanced nutritional supplement, Caplex, to cancer patients worldwide. Caplex contains a unique patent pending formulation created by an Oncologist and Clinical Dietitian. Caplex nutrition supplement provides cancer patients a comprehensive ...

BioMed Realty Trust Announces Exercise of Over-Allotment Option

SAN DIEGO, Oct. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR ) today announced that on October 1, 2008 the underwriter exercised its over-allotment option in full to purchase an additional 1,125,000 shares of common stock in connection with BioMed's previously announced of...

Sucampo Pharmaceuticals Announces Exercise and Closing of IPO Over-Allotment Option

BETHESDA, Md., Aug. 29 /PRNewswire-FirstCall/ -- Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP ) today announced that the underwriters for its initial public offering have exercised in full their option to purchase 562,500 shares of Sucampo's class A common stock to cover over-allotments and th...

Improved software makes direct mail an attractive option

EAU CLAIRE, WI - Many businesses, large and small, view direct mailing as a hit-or-miss attempt to reach potential customers and grab their attention. Postalsoft Business Edition 7.32c is a software system designed to give organizations more control over the direct mail process, and to make this fo...

Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option

Jeff Cunningham and Lynn Jordan Caliper Life Sciences, Inc., Applications Laboratory, Hopkinton, Massachusetts, USA Introduction The Z8 liquid handling device is an optional accessory to the Sciclone Advanced Liquid Handler (ALH). This device is designed t...

A highly sensitive ATP-luminescence assay using VICTOR2 with the dispenser option

INTRODUCTION In high sensitivity flash type luminescence assays the measurement is done just after dispensing the activating reagent or after a short delay time. Over the past years luminescence substrates have been improved towards providing more stable signal. These so-call...

Technical Specifications Accelerating Your Research with the BD FACSCanto High Throughput Sampler Option

Technical Specifications Accelerating Your Research with the BD FACSCanto High Throughput Sampler Option . Introduction The new BD High Throughput Sampler (HTS) provides fully automated and rapid sample acquisition. It is designed to speed throug...

NeurogesX Reports Second Quarter 2009 Results

...iddle East and Africa, including commercialization option and development funding for NGX-1998 and post-mark...r Qutenza, the agreement with Astellas included an option fee of EUR 5 million (approximately $7 million) as...s part of the co-development and commercialization option for NGX-1998. NeurogesX is currently evaluating th...

Viral Genetics Creates Subsidiary to Develop Cancer Therapy

...dition to our primary focus of HIV and AIDS." Viral Genetics has an option to acquire exclusive rights to the metabolic disruption technology from the...ped by Dr. Newell. Viral Genetics is completing negotiations to convert the option into an exclusive worldwide license covering a broad range of uses and spec...